
{{Act of Congress
| congress       = 113
| session        = 1
| pl             = 1
| title          = 
| override_previous = 
| statvolume     = 
| statpage       = 
| year           = 2013
| month          = 01
| day            = 18
| bill           = 315
| billtype       = hr
| notes          = 
| resolution     = 
| purpose        = To provide for the placement of certain synthetic drugs on Schedule I under the Controlled Substances Act.
}}

{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|H. R. 315}}


{{Center|IN THE HOUSE OF REPRESENTATIVES}}


{{Center|January 18, 2013}}


{{Center|
[[Wikipedia:Jo Ann Emerson|Mrs. Emerson ]]introduced the following bill; which was referred to the [[Wikipedia:United States House Committee on Energy and Commerce|Committee on Energy and Commerce ]], and in addition to the Committee on the [[Wikipedia:United States House Committee on the Judiciary|Judiciary ]], for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned}}


{{Center|A BILL}}

To provide for the placement of certain synthetic drugs on Schedule I under the Controlled Substances Act.
1. Short title


This Act may be cited as the “Synthetic Cathinones Control Act of 2013”.

2. Addition of synthetic drugs to Schedule I of the Controlled Substances Act


=(a) In general=

Notwithstanding any other provision of the Controlled Substances Act ( 21 U.S.C. 801 et seq. ) , the [[Wikipedia:United States Department of Justice|Attorney General ]]shall, not later than 60 days after the date of the enactment of this Act, issue a final order that schedules the following substances on schedule I under section 202(c) of that Act ( 21 U.S.C. 812(c) ) :: 3,4-methylenedioxymethcathinone (meth­yl­one).: Naphthylpyrovalerone (naphyrone).: 4-fluoromethcathinone (flephedrone).: 4-methoxymethcathinone (methedrone; Bk–PMMA).: Ethcathinone (N-ethylcathinone).: 3,4-methylenedioxyethcathinone (ethylone).: Beta-keto-N-methyl-3,4-benzo­di­oxy­oly­bu­tan­amine (butylone).: N,N-dimethylcathinone (metamfepramone).: Alpha-pyrrolidinopropiophenone (alpha-PPP).: 4-methoxy-alphapyrrolidinopropiophenone (MOPPP).: 3,4-meth­yl­ene­di­oxy­alpha­pyrrol­idino­pro­pio­phe­none (MDPPP).: Alpha-pyrrolidinovalerophenone (alpha-PVP).: 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (MDAI).: 3-fluoromethcathinone.: 4′-methyl-α-pyrrolidinobutiophenone (MPBP).
=(b) Conforming amendment To remove deadwood=

Subsection (c) of section 202 of the Controlled Substances Act ( 21 U.S.C. 802 ) is amended to read as follows:

==(c) Cross reference to Schedules of Controlled Substances==

Schedules I, II, III, IV, and V shall consist of the drugs and other substances (by whatever official name, common or usual name, chemical name, or brand name designated) that are set forth in the respective schedules in part 1308 of title 21, Code of Federal Regulations, as they may be amended from time to time, or in any successor regulation..
